Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck : An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - (CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651)
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-10-2016, Last updated: 2023-06-29 |
---|
ICTRP ID: |
EUCTR2016-000725-39-GB |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
CTG005716551 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG005716551 | ||
003 | DE-627 | ||
005 | 20230629100633.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210507s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG005716551 | ||
035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2016-000725-39-GB | ||
035 | |a (UBBS_Klinische_Studien_WHO)CA209-651 | ||
035 | |a (UBBS_Klinische_Studien_WHO)NCT02741570 | ||
035 | |a (UBBS_Klinische_Studien_WHO)2016-000725-39-ES | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |b An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - (CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-10-2016, Last updated: 2023-06-29 | ||
650 | 4 | |a Medical Condition: Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Phase: Phase 3 | |
650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2023) vom: 21. Juni |
773 | 1 | 8 | |g year:2023 |g day:21 |g month:06 |
856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000725-39 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 21 |c 06 |